Cellectis (CLLS) Reports Q3 Loss of $0.36/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016
November 22, 2016 5:01 PM EST- UCART19 Phase 1 trial on-going
- Successful cGMP Manufacturing for UCART123
- Strong cash position of $295 million1 as of September 30, 2016
- Additional grant of patent with broad claims covering fundamental use of gene editing technologies
- Revenues and other income of $12 million2 in the 3rd quarter of 2016
- Adjusted loss attributable to shareholders3 of $0.6 million2 in the 3rd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on... More
